All News

The Trump administration asked Congress for billions in COVID-19 assistance for Americans while a report said government responses in both the United States and the United Kingdom were suddenly being influenced by a grim analysis forecasting half a million to over 2 million deaths if the virus is allowed to run rampant without nonpharmaceutical interventions—ie, social isolation.

A special, noncontact boxing program was shown to potentially improve quality-of-life (QOL) and likelihood of exercise among patients with Parkinson disease compared with those who did not participate, according to preliminary study findings originally to be presented at the American Academy of Neurology’s 72nd Annual Meeting.

Michael D. Abramoff, MD, PhD, is the Robert C. Watzke, MD Professor of ophthalmology and visual sciences at the University of Iowa Carver College of Medicine. He is also a professor of electrical and computer engineering and a professor of biomedical engineering at the University of Iowa. Abramoff’s research interests include how autonomous artificial intelligence (AI) can be used to improve the lives of patients, with a focus on autonomous AI-based diagnostic and quantification algorithms for retinal disease. He is the founder and executive chairman of IDx Technologies, which developed IDx-DR, an FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Abramoff regarding the use of AI in the diagnosis of diabetic retinopathy.

Metastatic disease is the leading cause of death in the over 600,000 individuals worldwide who die of breast cancer each year. A new blood-based assay to detect minimal residual disease (MRD) in patients with stage 0 to 3 breast cancer was shown to have 100-fold greater sensitivity compared with digital droplet polymerase chain reaction.

If you have a primary care relationship, there is at least one health care provider who does know you: your primary care physician (PCP). Yet in the turmoil of admission and the danger of discharge, it has often been likely that the only physician on earth who knows you and your health would never know that you spent 3 days in the hospital. That is, until you recovered and told the person.

While the cell and gene therapies approved so far are indicated for rare diseases with small patient populations, the successes of chimeric antigen receptor-T (CAR-T) therapies and expanding interest from biopharma stress the need to rapidly scale the supply chain as these therapies move toward commercial availability for more disease states and larger patient populations.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text